T cell TET2 disruption cuts the breaks on antitumor CAR T cell therapy.

Zebley, Caitlin C; Youngblood, Ben

Zebley, Caitlin C; Youngblood, Ben.

Afiliación

Zebley CC; Department of Immunology, St Jude Children's Research Hospital, Memphis, TN 38105, USA; Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: Caitlin.Zebley@stjude.org.
Youngblood B; Department of Immunology, St Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: Benjamin.Youngblood@stjude.org.

Trends Immunol ; 44(6): 397-398, 2023 06.

Article en En | MEDLINE | ID: mdl-36959018

Asunto(s)

Dioxigenasas; Neoplasias; Animales; Ratones; Linfocitos T; Inmunoterapia Adoptiva/métodos; Receptores de Antígenos de Linfocitos T/genética; Neoplasias/terapia; Inmunoterapia/métodos; Proteínas de Unión al ADN/genética

Palabras clave

CAR T cells; TET2; cancer immunotherapy; epigenetics

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Dioxigenasas / Neoplasias Límite: Animals Idioma: En Revista: Trends Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google